Monday, May 12, 2014
S.A. is betting that a companion diagnostic can help its TREM1
inhibitors tamp down inflammation in the right sepsis patients and improve its
odds of success in an indication where the only approved drug was pulled from
the market three years ago.
Sepsis is a systematic
inflammatory response most often triggered by severe bacterial infection. A
major challenge to treatment is the immune response itself, which is both toxic
to the host and necessary to combat the infection. To improve survival, a
treatment must strike a delicate balance between the two.